Medpace (NASDAQ: MEDP) — Perfil da empresa, notícias e dados financeiros
Medpace is a full-service CRO supporting clinical trials for pharmaceutical and biotechnology industries, ensuring efficient therapy development.
Medpace
Medpace is a global contract research organization providing Phase I through Phase IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. Headquartered in Cincinnati, Ohio, the company offers integrated services including clinical trial management, study start-up, clinical monitoring, biostatistics, data management, medical writing, and regulatory affairs. Additionally, it operates central laboratories, bioanalytical laboratories, core imaging facilities, and cardiovascular safety labs to support drug and device development. The organization specializes in complex therapeutic areas such as oncology, cardiology, metabolic diseases, infectious diseases, and neuroscience, partnering with biopharmaceutical sponsors to execute multi-center global clinical trials.
Resumo
Operações
Produtos e/ou serviços de Medpace
- Clinical Trial Management: Comprehensive execution of early to late-phase global clinical studies, encompassing site selection, patient recruitment, clinical monitoring, biostatistics, data management, medical writing, and regulatory filings across primary therapeutic areas including oncology, cardiology, and metabolic disorders.
- Central Laboratory Services: Integrated safety testing, biomarker development, microbiology capabilities, and biorepository storage conducted through purpose-built laboratory facilities supporting multi-center international trial programs with standardized analytical procedures, automated data workflows, and centralized logistics.
- Bioanalytical Laboratory Services: Specialized discovery and development testing services, including pharmacokinetic and toxicokinetic evaluation, immunogenicity assays, biomarker measurement, and anti-drug antibody profiling to support preclinical compounds and human clinical study analysis.
- Core Imaging Services: Comprehensive medical imaging operational support and quantitative image analysis covering nuclear medicine, oncology, musculoskeletal, central nervous system, and cardiovascular endpoints utilizing standardized imaging protocols across participating clinical investigative sites.
- Electrocardiography and Cardiac Safety: Centralized electrocardiogram monitoring, continuous telemetry data acquisition, and wearable biosensor integration providing cardiac risk evaluation, safety data analysis, and expert medical interpretation throughout all phases of biopharmaceutical clinical development.
- Phase I Clinical Research Units: Specialized clinical facilities dedicated to executing complex early-phase clinical trials, conducting first-in-human studies, bioavailability assessments, pharmacokinetic evaluations, and intensive pharmacodynamic protocol execution for biopharmaceutical sponsors.
equipe executiva do Medpace
- August James TroendleCEO, President & Chairman
- Stephen P. EwaldChief Compliance Officer, General Counsel & Corporate Secretary
- Brad W. HansmanExecutive Vice President of Operations
Principais indicadores financeiros
Resultados divulgados pela Medpace, em USD.
- Cap. de mercado
- 18,8 bi
- Receita (TTM)
- 2,8 bi
- P/L
- 37.4
- LPA (diluído, TTM)
- 18.0
- Dividend yield
- —
- Margem de lucro
- 18.2%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 2,5 bi | 534,9 mi | 451,1 mi | |
| 2,1 bi | 446,9 mi | 404,4 mi | |
| 1,9 bi | 336,8 mi | 282,8 mi | |
| 1,5 bi | 278,7 mi | 245,4 mi |